Compass Pathways (NASDAQ: CMPS) this morning issued a brief release, indicating it has been granted a fifth patent in the United States. The patent is related to what is referred to as crystalline psilocybin.
More specifically, the patent covers methods of treating treatment-resistant depression through the use of crystalline psilocybin. The patent also covers the use of oral dosage forms of the psilocybin with an excipient, which in layman terms means the psilocybin can be used in oral dosage format with a bulking agent, which can boost stability or bioavailability.
Notably, the tech protected by this latest patent is being utilized in COMP360, the firms formulation of synthesized psilocybin it is currently investigating for treatment against treatment-resistant depression.
Sponsored · Antimony Resources
The patent is the fifth for the company in the US, and its tenth globally. The firm currently holds two patents in each of Hong Kong and the United Kingdom, and one in Germany. As per the company, the patents “enable [Compass] to continue to do the highest quality clinical research.”
Compass Pathways last traded at $30.23 on the Nasdaq.
Information for this briefing was found via Edgar and Compass Pathways. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
